These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prevention of bubonic and pneumonic plague using plant-derived vaccines. Alvarez ML; Cardineau GA Biotechnol Adv; 2010; 28(1):184-96. PubMed ID: 19931370 [TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine. Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064 [TBL] [Abstract][Full Text] [Related]
10. Rational considerations about development of live attenuated Yersinia pestis vaccines. Sun W; Curtiss R Curr Pharm Biotechnol; 2013; 14(10):878-86. PubMed ID: 24372254 [TBL] [Abstract][Full Text] [Related]
11. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague. Sanapala S; Rahav H; Patel H; Sun W; Curtiss R Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051 [TBL] [Abstract][Full Text] [Related]
12. A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice. Bozue J; Cote CK; Webster W; Bassett A; Tobery S; Little S; Swietnicki W FEMS Microbiol Lett; 2012 Jul; 332(2):113-21. PubMed ID: 22537022 [TBL] [Abstract][Full Text] [Related]
13. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Alvarez ML; Pinyerd HL; Crisantes JD; Rigano MM; Pinkhasov J; Walmsley AM; Mason HS; Cardineau GA Vaccine; 2006 Mar; 24(14):2477-90. PubMed ID: 16442673 [TBL] [Abstract][Full Text] [Related]
14. Dual route vaccination for plague with emergency use applications. Moore BD; New RRC; Butcher W; Mahood R; Steward J; Bayliss M; MacLeod C; Bogus M; Williamson ED Vaccine; 2018 Aug; 36(34):5210-5217. PubMed ID: 30017148 [TBL] [Abstract][Full Text] [Related]
15. Plague vaccines and the molecular basis of immunity against Yersinia pestis. Quenee LE; Schneewind O Hum Vaccin; 2009 Dec; 5(12):817-23. PubMed ID: 19786842 [TBL] [Abstract][Full Text] [Related]
16. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457 [TBL] [Abstract][Full Text] [Related]
18. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague. Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198 [TBL] [Abstract][Full Text] [Related]
20. Developing live vaccines against plague. Sun W; Roland KL; Curtiss R J Infect Dev Ctries; 2011 Sep; 5(9):614-27. PubMed ID: 21918302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]